Gary Glick, Odyssey Therapeutics CEO

Ex­clu­sive: Gary Glick’s Odyssey rais­es $101M Se­ries C as first im­munol­o­gy drugs ap­proach the clin­ic

Odyssey Ther­a­peu­tics has raised $101 mil­lion in a new round, as the Boston biotech pre­pares for its first drug can­di­dates to soon en­ter the clin­ic, CEO Gary Glick told End­points News.

Glick is a chem­istry pro­fes­sor turned se­r­i­al en­tre­pre­neur who found­ed Lyc­era, IFM Ther­a­peu­tics, and Scor­pi­on Ther­a­peu­tics. He’s helped dis­cov­er six pro­grams that have reached the clin­ic, with three or four still pro­gress­ing, he said. But bring­ing a drug through ap­proval is “one of the pin­na­cle sci­en­tif­ic chal­lenges” that he hopes to achieve with Odyssey. And in just two years, the com­pa­ny has raised near­ly half a bil­lion dol­lars to de­vel­op a suite of drugs in im­munol­o­gy and on­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.